Overview

Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Status:
Active, not recruiting

Trial end date:
2024-10-04

Target enrollment:

Participant gender:

Summary

This is a single-arm, open-label, multicenter, phase 4 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with relapsed or refractory Systemic Anaplastic Large Cell Lymphoma (SALCL).

Phase:

Phase 4

Details

Lead Sponsor:

Millennium Pharmaceuticals, Inc.

Treatments:

Antibodies
Antibodies, Monoclonal
Brentuximab Vedotin